Drug Profile
Ficlatuzumab companion diagnostic - Biodesix
Alternative Names: VeriStrat testLatest Information Update: 04 Dec 2023
Price :
$50
*
At a glance
- Originator Biodesix
- Developer AVEO Oncology; Biodesix
- Class Diagnostic agents; Protein diagnostics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 25 Feb 2021 No development reported - Phase-I/II for Non-small cell lung cancer (Diagnosis) in Hong Kong, Malaysia, Philippines, Singapore, South Korea, Thailand, Taiwan (unspecified route)
- 24 Oct 2014 Veristrat® gets added into the National Comprehensive Cancer Network (NCCN) guidelines for Non-small cell lung cancer
- 06 Jun 2011 Phase-III clinical trials in Non-small cell lung cancer (Diagnosis) in Italy (unspecified route)